Navigation Links
ViroPharma To Participate In Two May Healthcare Investor Conferences
Date:5/9/2013

EXTON, Pa., May 9, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody , director of investor relations, will present at the 2013 Bank of America Merrill Lynch Healthcare Conference at 11:20 AM PT (2:20 PM ET) on Tuesday, May 14, 2013.  The conference is being held at the Encore at the Wynn Hotel in Las Vegas, NV.

ViroPharma also announced that Charles Rowland , vice president and chief financial officer of ViroPharma, will present at the Deutsche Bank 38th Annual Healthcare Conference at 9:20 AM ET on Wednesday, May 29, 2013.  The conference is being held at the Westin Boston Waterfront Hotel.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Participate in Two December Healthcare Investor Conferences
2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
3. ViroPharma Announces First Quarter 2013 Financial Results
4. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
5. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
6. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
7. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
8. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
9. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
10. AVANIR Pharmaceuticals To participate in two conferences in March
11. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... , ... September 21, 2017 , ... ... clinical research sector professionals, has announced the addition of 5 new courses to ... - Compliance with Regulation 21 CFR Part 11 on Electronic Records and ...
(Date:9/21/2017)... New Haven, CT (PRWEB) , ... September 21, ... ... company developing bioresorbable scaffold technology, today announced the election of Paul Hermes, Entrepreneur ... Board of Directors. , Biorez has developed a proprietary, tissue-engineered scaffold for ...
(Date:9/20/2017)... ... September 20, 2017 , ... Diversity focused business accelerator, ... the Growth pitch competition to uncover the top technology-driven, women-led startups in Boston, MA, ... part of each city’s entrepreneurial events going on that week – in Boston, it ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... of a study examining the effects of exoskeleton-assisted walking on gait parameters ... (SCI). The article, "Neuromechanical adaptations during a robotic powered exoskeleton assisted walking ...
Breaking Biology Technology:
(Date:8/23/2017)... public,s help is being enlisted in what,s thought to be the biggest ... human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to date ... project's goal is to help advance scientific knowledge of the role of ... The ...
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ) ... any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board ... Delta,s biometric boarding ... Club is now integrated into the boarding process to allow eligible ...
Breaking Biology News(10 mins):